Reply to Missing Parts/ Incomplete Application

Firm Name

Signature
Printed name

Reply to Missing Parts under 37 CFR 1.52 or 1.63

Irving Newman

AVENTIS PHARMACEUTICALS INC.

REGULVED FEUTAL AGRENIER

APROVED for use through 07/31/2006, OMB 0651-0031

Under the Papetwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it displays a valid OMS control number.								
			Application Number	10/608,				
TRÄNSMITTAL FORM			Filing Date	June 26, 2003 Florence BORDON-PALLIER et al.				
			First Named Inventor					
			Art Unit	1614				
(to be used for all correspondence after initial filing)			Examiner Name	To Be Assigned				
Total Number of Pages In This Submission 2		2	Attorney Docket Number	2541 US CNT				
ENCLOSURES (Check all that apply)								
	Fee Transmittal Form		Drawing(s)			After Allowance Communication to TC		
	Fee Attached		Licensing-related Papers			Appeal Communication to Board of Appeals and Interferences		
	Amendment/Reply		Petition Petition to Convert to a			Appeal Communication to TC (Appeal Notice, Eriof, Reply Brief)		
	After Final	ᄖ	Provisional Application Power of Attorney, Revocation			Proprietary Information		
	Affidavits/declaration(s)	ᆜᆜ	Change of Correspondence A		1	Status Letter		
	Extension of Time Request		Terminal Disclaimer			Other Englosure(s) (please Identify below):		
	Express Abandonment Request		Request for Refund		į			
	Information Disclosure Statement		CD, Number of CD(s)					
			Landscape Table on CD					
	Certified Copy of Priority Document(s)	Rema	rks			· · · · · · · · · · · · · · · · · · ·		

Date	April 04, 2005	Reg. No. 22,638
	CERTIFICATI	OF TRANSMISSION/MAILING
sumicient pos	ify that this correspondence is being facsimile t stage as first class mall in an envelope address wn below: (USPTO FAX NO. 703-672-9306	ransmitted to the USPTO or deposited with the United States Postal Service with ed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on
Signature	Barile L.	Sec.
Typed or prin	nted name Bonita L. Stein	Date April 04, 2005

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

This collection of information is required by 97 CFR 1.5. The information is required to obtain or ratain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. This will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Potent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patients, P.O. Box 1450, Alexandria, VA 22313-1450.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

THURAL RUI GENUE APR 0 4.2005

ALCOVED

In re Application of

Examiner:

To Be Assigned

F. Bordon-Pallier, et al

Art Unit:

1614

Application No.:

10/606,424

Filed:

June 26, 2003

Title:

Novel Purine Derivatives, Preparation

Method and Use as Medicines

Certificate of Mailing or Transmission

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop address below, or being facsimile transmitted to the

USPTO, on the date indicated below.

Date of Deposit April 4, 2005

Printed Name of Person Signing Certificare Honnie Stein

STATUS INQUIRY

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

The Applicants request a Status Inquiry for Application Serial No. 10/606,424, filed June 26, 2003.

Respectfully submitted,

rying Newman, Reg. No. 22,638 Attorney/Agept for Applicant

Aventis Pharmaceuticals Inc. Patent Department Route #202-206 / P.O. Box 6800 Bridgewater, NJ 08807-0800 Telephone (908) 231-2785 Telefax (908) 231-2626

Aventis Docket No. 2541US CNT